These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35904005)

  • 21. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
    Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
    Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.
    Gontijo AV; Brillault J; Grégoire N; Lamarche I; Gobin P; Couet W; Marchand S
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3942-9. PubMed ID: 24798283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model.
    Tang C; Ou-Yang CX; Chen WJ; Zou C; Huang J; Cui C; Yang S; Guo C; Yang XY; Lin Y; Pei Q; Yang GP
    Eur J Pharm Sci; 2022 Jan; 168():106055. PubMed ID: 34742834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.
    Su FY; Srinivasan S; Lee B; Chen J; Convertine AJ; West TE; Ratner DM; Skerrett SJ; Stayton PS
    J Control Release; 2018 Oct; 287():1-11. PubMed ID: 30099019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of 2-phenoxyethanol and its major metabolite, phenoxyacetic acid, after dermal and inhaled routes of exposure: application to development PBPK model in rats.
    Kwon M; Park JB; Kwon M; Song J; Yeo CS; Bae SH
    Arch Toxicol; 2021 Jun; 95(6):2019-2036. PubMed ID: 33844041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods.
    Himstedt A; Borghardt JM; Wicha SG
    J Pharmacokinet Pharmacodyn; 2022 Apr; 49(2):135-149. PubMed ID: 34585333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
    Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
    Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin.
    Doan TV; Grégoire N; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC
    Eur J Pharm Sci; 2013 Jan; 48(1-2):223-30. PubMed ID: 23159665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration.
    Liu C; Shi J; Dai Q; Yin X; Zhang X; Zheng A
    Drug Dev Ind Pharm; 2015 Feb; 41(2):272-8. PubMed ID: 24252110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition.
    Bäckman P; Tehler U; Olsson B
    J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):108-117. PubMed ID: 27740878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
    Miyazaki M; Sawada S; Nishide T; Iwanaga K; Morimoto K; Kakemi M
    Biol Pharm Bull; 2000 Jan; 23(1):87-96. PubMed ID: 10706418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applications of minimal physiologically-based pharmacokinetic models.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):711-23. PubMed ID: 23179857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics.
    Epps QJ; Epps KL; Young DC; Zobell JT
    Pediatr Pulmonol; 2020 Jan; 55(1):33-57. PubMed ID: 31609097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy.
    Mukker JK; Singh RS; Derendorf H
    Adv Drug Deliv Rev; 2015 May; 85():57-64. PubMed ID: 25770775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY
    Shao J; Chen MJ; Kuehl PJ; Hochhaus G
    Drug Dev Ind Pharm; 2019 Jul; 45(7):1101-1110. PubMed ID: 31039626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model.
    Raut A; Dhapare S; Venitz J; Sakagami M
    Biopharm Drug Dispos; 2020 Feb; 41(1-2):32-43. PubMed ID: 31691979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically-based pharmacokinetic model for Fentanyl in support of the development of Provisional Advisory Levels.
    Shankaran H; Adeshina F; Teeguarden JG
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):464-76. PubMed ID: 23732079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Physiologically Based Pharmacokinetic Model for Naphthalene With Inhalation and Skin Routes of Exposure.
    Kapraun DF; Schlosser PM; Nylander-French LA; Kim D; Yost EE; Druwe IL
    Toxicol Sci; 2020 Oct; 177(2):377-391. PubMed ID: 32687177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Verification of a Linked
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.